Skip to main content
European Commission logo print header

Innovative highly concentrated Omega-3 Specialized Nutrition Product

Project description

A novel omega-3 emulsion for special medical purposes

Omega-3 fatty acids play a key role in cell membrane health and human overall wellbeing, including brain, heart and eye health. Our bodies cannot produce them, and most people do not get enough of them in their diets. Studies suggest that omega-3 fatty acids can also be beneficial to cancer patients undergoing chemotherapy, reducing complications secondary to cancer and its treatment. The EU funded LIFEOMEGA project will support the Spanish SME Solutex in preparation of its highly concentrated, emulsified omega-3 (EPA) nutritional supplement for industrial-scale production and commercialisation. The emulsion can be used as a stand-alone oral supplement and potentially as a supplement to other liquid formulations for special medical purposes.


The objective of the project is the industrial and market development of a high concentrated Omega3 EPA nutritional product addressed to improve the health of cancer patients.

LIFEOMEGA-cancer can be considered one chemotherapy essential nutrient co-adjuvant by overcoming:

1. The deficit of necessary level essential Omega3 EPA fatty acid by one efficient concentration and daily dosage (min 2.2 g EPA per day)
2. On a convenient way for the patient overcoming unpleasant fishy taste and with one unique delivery form

The product is protected by IP and constitutes a unique product and solution, not present in the market. Moreover, it is flavourized, and being an emulsion, it can be conveniently delivered in other liquids. These features make the product a complete breakthrough Medical Food in the essential nutrition market, both in Europe and in the USA.

Cancer patients receiving chemotherapy will be highly benefitted with LIFEOMEGA product; they can have their treatments (as cancer chemo/radiotherapy treatments) outcomes improved, their length of hospital stay reduced, and their quality of life during and after treatment increased. The high convenience allows the consumption of fewer dosages to achieve the targeted Omega3 levels.

LIFEOMEGA has a great potential, as it is estimated that cancer patients recieving chemotherapy unfortunately won't be less than 1 millon / year during the next 11 years, in USA, Spain, France, Germany, UK and Italy.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 1 712 046,88
Ctr de barajas 24 3-4 parque empresarial omega edificio gamma
28108 Alcobendas madrid

See on map

Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 765 977,58